medmix Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	no data
Board average tenure	2.6yrs

Recent management updates

Recent updates

medmix AG (VTX:MEDX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

Aug 11

CEO

medmix has no CEO, or we have no data on them.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Metzger	Director	2.6yrs	CHF 144.00k	0.0039% CHF 14.3k
Susanne Hundsbæk-Pedersen	Director	less than a year	no data	no data
Rene Willi	Director	2.6yrs	CHF 146.00k	0.0015% CHF 5.6k
Marco Musetti	Independent Vice Chairman of the Board	3.2yrs	CHF 163.00k	0.032% CHF 118.4k
Barbara Angehrn	Independent Director	2.6yrs	CHF 146.00k	0.0015% CHF 5.6k
Rob Hoedt	Independent Chairman	2.6yrs	CHF 302.00k	0.0017% CHF 6.3k
Daniel Flammer	Director	2.6yrs	CHF 146.00k	0.0015% CHF 5.6k

2.6yrs

Average Tenure

55yo

Average Age

Experienced Board: MEDX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

medmix Management

Management criteria checks 0/4

Key information

Recent management updates

medmix AG, Annual General Meeting, Apr 24, 2024

High number of new and inexperienced directors

Recent updates

medmix AG (VTX:MEDX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough

First half 2024 earnings released: EPS: CHF0.12 (vs CHF0.18 in 1H 2023)

Consensus EPS estimates fall by 11%

Price target decreased by 9.8% to CHF27.50

Consensus EPS estimates increase by 40%

medmix AG to Report Fiscal Year 2024 Final Results on Feb 26, 2025

Now 21% overvalued after recent price rise

Upcoming dividend of CHF0.50 per share

Consensus EPS estimates fall by 24%, revenue upgraded

New minor risk - Earnings quality

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% overvalued

Consensus EPS estimates fall by 26%

Price target decreased by 10% to CHF30.50

New minor risk - Financial data availability

medmix AG, Annual General Meeting, Apr 24, 2024

Consensus EPS estimates fall by 19%

medmix (VTX:MEDX) Is Reinvesting At Lower Rates Of Return

An Intrinsic Calculation For medmix AG (VTX:MEDX) Suggests It's 21% Undervalued

Now 20% undervalued after recent price drop

Price target increased by 13% to CHF34.00

Investors Could Be Concerned With medmix's (VTX:MEDX) Returns On Capital

Consensus EPS estimates fall by 25%

First half 2023 earnings released: EPS: CHF0.18 (vs CHF0.23 in 1H 2022)

medmix AG (SWX:MEDX) completed the acquisition of 70% stake in Guangdong Qiaoyi Plastic Co. LTD.

Upcoming dividend of CHF0.50 per share at 2.3% yield

Consensus EPS estimates increase by 17%

Price target decreased by 12% to CHF30.00

There May Be Reason For Hope In medmix's (VTX:MEDX) Disappointing Earnings

Full year 2022 earnings released: EPS: CHF0.28 (vs CHF1.07 in FY 2021)

Consensus EPS estimates fall by 12%

Consensus forecasts updated

Consensus forecasts updated

medmix (VTX:MEDX) May Have Issues Allocating Its Capital

medmix AG (SWX:MEDX) agreed to acquire unknown majority stake in Guangdong Qiaoyi Plastic Co. LTD.

Medmix AG agreed to acquire plastics business of Universal de Suministros, S.L., Spain.

First half 2022 earnings released: EPS: CHF0.58 (vs CHF0.55 in 1H 2021)

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 13%

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS misses analyst expectations

Now 20% undervalued after recent price drop

CEO

Board Members

Average Tenure

Average Age